As a biopharmaceutical company, Omeros Corporation continues to engage in the discovery and development of novelty therapeutics that are intended to address the unmet areas of medicine. The business is traded publicly on the NASDAQ Global Market and trades its stocks using the symbol OMER.
Incorporated in June 1994, Omeros Corporation engages in the development of small-molecule and protein therapeutics that target disorders of the central nervous system, inflammation and coagulopathies. They have several product candidates that are in various phases of clinical trials. Their pipeline products include the MASP (OMS721), which is intended as a treatment for complement-mediated disorders, PPARy (OMS405) for Addiction, OMS201 for Urology, PDE10 (OMS824) for CNS Disorders and OMS103 for Arthroscopy.
Headquartered in Seattle, Washington, Omeros Corporation continues to leverage its drug development on its proprietary PharmacoSurgery platform. It partners with other pharmaceutical companies to hasten the development of its products. It is listed as a component of the Wilshire 5000 Index.